1. Namey E, Agot K, Ahmed K, Odhiambo J, Skhosana J, Guest G and Corneli A. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Culture, Health & Sexuality 2016. DOI: 10.1080/13691058.201164899
  2. Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor KJ, Malamatsho F, Odhiambo J, Skhosana J and Van Damme L. Participants’ Explanations for Nonadherence in theFEM-PrEP Clinical Trial. J Acquired Immune Deficiency Syndrome 2016. 71 (4): 452-461.
  3. Corneli A, Yacobson I, Agot K and Ahmed K. Guidance for Providing Informed-Choice Counseling on Sexual Health for Women Interested in Pre-Exposure Prophylaxis in Kenya and South Africa.AIDS Patient Care STDS.Published ahead of print.
  4. Deese J, Masson L, Miller W, Cohen M, Morrison C, Wang M, Ahmed K, Agot K, Crucitti T, Abdellati S andVan Damme L.Injectable Progestin-Only Contraception is Associated with Increased Levels of Pro-Inflammatory Cytokines in the Female Genital Tract.American Journal of ReproductiveImmunolology.2015; 74 (4): 357-367.
  5. Malahleha M, Ahmed K, Deese J, Nanda K, Van Damme L, De Baetselier I and Burnett RJ. Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report. Journal of Medical Case Reports 2015; 9: 207. DOI 10.1186/s13256-015-0679-4.
  6. Friedland BA, Stoner M, Chau MM, Plagianos MG, Govender S, Morar N, Altini L, Skoler-Karpoff S, Ahmed K, Ramjee G, Monedi C, Maguire R and Lahteenmaki P. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial. Aids and Behaviour 2015. DOI 10.1007/s10461-015-1123-x.
  7. Corneli A, Namey E, Ahmed K, Agot K, Skhosana J, Odhiambo J and Guest G. Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. Aids Patient Care and STDs 2015; 29 (9): DOI: 10.1089/apc.2015.0038
  8. Corneli A, Field S, Namey E, Agot K, Ahmed K, Odhiambo J, Skhosana J and Guest G. Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP.PloS One 2015; DOI:10.1371/journal.pone.0129177.
  9. Kelly CA, Friedland BA, Morar NS, Katzen LL. , Ramjee G, Mokgatle MM and Ahmed K. Tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa. Culture, Health & Sexuality 2015. DOI: 10.1080/13691058.2015.1030451.
  10. Agot K, Taylor D, Corneli A, Wang M, Ambia J, Kashuba A, Parker C, Lemons A, Malahleha M, Lombaard J, Van Damme L. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. AIDS Behav. 2015; 19 (5): 743-751.
  11. Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F and Van Damme L. Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial. Plos One 2015. DOI:10.1371/journal.pone.0125458.
  12. Corneli L, McKenna K, Perry B,Ahmed K, Ago K, Malamatsho F,Skhosana J,Odhiambo  J, Van Damme L. The Science of Being a Study Participant: FEM-PrEP Participants’ Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills. J Acquired Immune Deficiency Syndrome 2015; 68(5): 578-584.
  13. Parker C, Corneli A, Agot K, Odhiambo J, Asewe J, Ahmed K, Skhosana J,Ratlhagana M, Lanham M, Wong C, Deese J, Manongi R, Van Damme L . Lessons learnt from implementing an empirically informed recruitment approach for FEM-PrEP, a large HIV prevention clinical trial. Open Access Journal of clinical Trials2015; 7: 1-9.
  14. Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D, for the FEM-PrEP Study Group. Pregnancy and Contraceptive Use Among Women Participating in the FEM-PrEPTrial.Acquir Immune Defic. Syndr2015; 68 (2): 196 – 203.
  15. Mandala J, Nanda K , Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, Malahleha M, Manongi R, Taylor D and Van Damme L. Liver and renal safety of tenofovirdisoproxilfumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacology and Toxicology2014; 15 (1):77.
  16. Corneli A, Wang M, Agot K,Ahmed K,Lombaard J, Van Damme L, for the FEM-PrEP Study Group. Perception of HIV Risk and Adherence to a Daily, Investigational Pill for HIV Prevention in FEM-PrEP.Journal of Acquired Immune Deficiency Syndromes 2014; 67 (5): 455-575.
  17. Corneli AL, McKenna K, Headley J, Ahmed K,Odhiambo J, Skhosana J, Wang M and Agot K for the FEM-PrEP Study Group. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South AfricaJournal of the International AIDS Society2014, 17 (Suppl 2): 19152
  18. Evens E, Tolley E, Headley J, McCarraher D, Hartmann M, Mtimkulu VT, Manenzhe K, Hamela G, Zulu F.  Identifying factors that influence pregnancy intentions: evidence from South Africa and Malawi. Culture, Health and Sexuality 2014; 29:1-16.
  19. Grant R.M, Liegler T, Defechreux P, Kashuba A.D.M, Taylor D, Abdel-Mohsen M., Deese J, Fransen K, De Baestelier I, Cricitti T, Bentley G, Agingu W, Ahmed K and Van Damme L. Drug resistance and plasma viral RNA level after ineffective use of pre-exposure prophlyaxi in Women. AIDS 2014;29(3):331-337.
  20. Headly J, Corneli A., Agot K, Ahmed K, Wang M, Odhiambo J, Skhosana J, Tharaldson J, van Damme L, MacQueen K, For the FEM-PrEP Study Group. The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa. PloS One2014; 17: 9 (9).
  21. CorneliAL,Deese J, Wang M, Taylor D, Ahmed K, Agot K, Lombaard J, Monangi R, Kapiga S, Kashuba A and van Damme L, for the FEM-PrEP Study Group. FEM-PEP Adherence Patterns and Factors Associated with Adherence to a Daily oral Study Product for Pre-exposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes 2014; 66 (3): 324-331.
  22. Schenk KD,Friedland BA, Chau M, Stoner M, Plagianos MG, Skoler-Karpoff S, Palanee T, Ahmed K, Rathlagana MJM , Mthembu PN , and Ngcozela N. Enrollment of Adolescents Aged 16-17 Years Old in Microbicide Trials: An Evidence-Based Approach.Journalof Adolescent Health 2014; 54 (6): 654-662.
  23. Malahleha M, Mokwena K, Ahmed K. Knowledge and Perceptions of Vaginal Microbicides among Healthcare Postgraduate Students at the University of Limpopo. AIDS Res Hum Retroviruses 2014; 30 (S1): A163-A164.
  24. Mack N, Kirkendale S, Omullo P, Odhiambo J, Masiki M, Siguntu P, Ratlhagana M, Agot K, Ahmed K, Kapiga S, Lombaard J, van Damme L, Corneli A.  Implementing good participatory practice guidelines in the FEM-PrEPPreexposureProfilaxis Trial for HIV PreventionAmong African Women: a focus on local stakeholder involvement.Journal of clinical Trials 2013; 5:127-135.
  25. Ahmed K, Malahleha M, Deese J, Monedi C and van Damme L. Elevated liver transaminases, human immune deficiency virus (HIV) seroconversion and rapid progression to AIDS in a HIV prevention clinical trial participant: A case report Journal of AIDS and HIV Research 2013; 5(3): 65-69.
  26. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M Pre-exposure prophylaxis for HIV infection among African women. The New England Journal of Medicine 2012; 367: 411-422.
  27. Morrison C, Skoler-Karpoff S, Kwoka C, Chena P L, Wijgert J, Gehret-PlagianosMPatel S, Ahmed K, et al.Hormonal Contraception and the Risk of HIV Acquisition among Women in South Africa.AIDS 2012; 4:497-504.
  28. Marais Gawarecki D, Allan B, Ahmed K, Altini L, Cassim N, Gopaleng F, Hoffman M, Ramjee G, Williamson A-L. The Effectiveness of Carraguard, a Vaginal Microbicide, in protecting women against high-risk Human Papilloma-Virus infection. Antiviral therapy 2011; 16(8):1219-1226.
  29. Mensch BS, Hewett PC, Abbott S, Rankin J, Littlefield S, Ahmed K, Cassim N, Patel S,  Ramjee G, Palanee T, Mierzwa S, Skoler-Karpoff S. Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial in South Africa: An Interview Mode Experiment Using a Placebo Gel. AIDS and Behaviour 2011; 15: 407-421.
  30. Said HM, Ahmed K, Burnett R, Allan BR, Williamson A-L, Hoosen, AA. HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community based Microbicide study in Pretoria, South Africa. Journal of Clinical Virology 2009;44: 318-321.
  31. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, GehretPlagianos M, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomized, double-blind, placebo-controlled trial. Lancet 2008. 372:1977-1987.
  32. Ahmed K, Cassim N. HIV prevention using vaginal microbicides: an update.JIMASA 2007;14:11-14.
  33. de Kock A, Skoler S, Ahmed K, Govender S. Enrolling Adolescents in Research on HIV: Young Women Must Be Included. PLoS Med 2006; 3 (12): 2458-2463.
  34. SkolerS,Govender S, Altini L, Ahmed K, Waldron D, Myer L, Lahteenmaki P, Fleming Richardson B. Risks in the use of an unblinded-control group. Journal of Infectious Diseases 2005; 191: 1378-1380.
  35. Skoler S, Govender S, Altini L, Ahmed K, Waldron D, Myer L, Lahteenmaki P. Control Groups in Microbicide Trials: In defense of Orthodoxy. Correspondence Article. Journal of Infectious Diseases 2005;191:1378-1379.
Download in PDF Format